Fred Alger Management LLC lessened its holdings in McKesson Co. (NYSE:MCK – Free Report) by 99.3% during the 3rd quarter, Holdings Channel reports. The firm owned 1,581 shares of the company’s stock after selling 240,681 shares during the quarter. Fred Alger Management LLC’s holdings in McKesson were worth $782,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Massachusetts Financial Services Co. MA grew its holdings in McKesson by 2.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 4,943,520 shares of the company’s stock valued at $2,444,175,000 after buying an additional 138,685 shares during the last quarter. FMR LLC boosted its stake in shares of McKesson by 17.3% during the third quarter. FMR LLC now owns 2,968,239 shares of the company’s stock valued at $1,467,557,000 after acquiring an additional 438,423 shares during the last quarter. Legal & General Group Plc increased its position in McKesson by 2.9% during the 2nd quarter. Legal & General Group Plc now owns 1,297,620 shares of the company’s stock worth $757,862,000 after purchasing an additional 36,583 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in McKesson by 55.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,189,377 shares of the company’s stock valued at $588,048,000 after purchasing an additional 425,875 shares during the last quarter. Finally, AQR Capital Management LLC lifted its holdings in McKesson by 7.9% in the 2nd quarter. AQR Capital Management LLC now owns 857,611 shares of the company’s stock valued at $500,879,000 after purchasing an additional 62,875 shares in the last quarter. 85.07% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In related news, CEO Brian S. Tyler sold 3,753 shares of the business’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $561.10, for a total value of $2,105,808.30. Following the transaction, the chief executive officer now owns 78,586 shares in the company, valued at approximately $44,094,604.60. The trade was a 4.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.11% of the company’s stock.
Analysts Set New Price Targets
Read Our Latest Analysis on McKesson
McKesson Trading Up 0.3 %
Shares of NYSE MCK opened at $628.50 on Monday. The stock has a fifty day moving average price of $542.22 and a 200 day moving average price of $560.02. McKesson Co. has a 12-month low of $431.35 and a 12-month high of $637.51. The company has a market cap of $79.78 billion, a P/E ratio of 32.55, a P/E/G ratio of 1.36 and a beta of 0.44.
McKesson (NYSE:MCK – Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $7.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.88 by $0.19. The business had revenue of $93.65 billion during the quarter, compared to analyst estimates of $89.33 billion. McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. The company’s revenue for the quarter was up 21.3% compared to the same quarter last year. During the same quarter last year, the firm earned $6.23 earnings per share. On average, sell-side analysts forecast that McKesson Co. will post 32.73 EPS for the current fiscal year.
McKesson Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, January 2nd. Stockholders of record on Monday, December 2nd will be given a dividend of $0.71 per share. The ex-dividend date is Monday, December 2nd. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.45%. McKesson’s payout ratio is currently 14.71%.
About McKesson
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Read More
- Five stocks we like better than McKesson
- Health Care Stocks Explained: Why You Might Want to Invest
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
- Low PE Growth Stocks: Unlocking Investment Opportunities
- ServiceNow: Will the High-Flyer Finally Split in 2024?
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCK – Free Report).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.